Iomab-B

Phase 3Monoclonal antibody

AActinium Pharmaceuticals

Iomab-B is one of 71 small molecule programs targeting Diffuse Large B-Cell Lymphoma. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Diffuse Large B-Cell LymphomaActive, not recruiting

Acute Myeloid LeukemiaActive, not recruiting

Diffuse Large B-Cell LymphomaPhase 1/Phase 2

Active, not recruiting

Acute Myeloid LeukemiaPhase 3

Active, not recruiting

Competition

Competitive Landscape

804 competitors in Acute Myeloid Leukemia

#DrugCompanyPhaseTrials

Empaveli

Gilead

Phase 3

4 2

Zarnestra

KKura Oncology, Inc.

Phase 3

9 3

Intron a

Sanofi

Phase 3

1 4

Lenograstim

Sanofi

Phase 3

1 5

Caspofungin Acetate

Merck & Co.

Phase 3

1 6

Experimental

Biogen

Phase 3

1 7

Oblimersen Sodium

NNational Cancer Institute (NCI)

Phase 3

3 8

GM-CSF

YY-mAbs Therapeutics

Phase 3

1 9

Sapacitabine

CCyclacel Pharmaceuticals, Inc.

Phase 3

1 10

Low-Dose Cytarabine

Bristol-Myers Squibb

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 3Active, not recruiting

Acute Myeloid Leukemia

NCT02665065

Q2 2030

Phase 1/2Recruiting

Diffuse Large B-Cell Lymphoma

NCT06768905

Clinical

Trials by Indication[1]

Acute Myeloid Leukemia1 trial

Study of Iomab-B vs. Conventional Care in Older Subjects With Active, Relapsed or Refractory Acute Myeloid Leukemia

Active, not recruiting·AActinium Pharmaceuticals·Phase 3·NCT02665065·153 enrolled

Diffuse Large B-Cell Lymphoma1 trial

Study of IOMAB-ACT Followed by CAR-T Cell Therapy for Patients Relapsed or Refractory (Diffuse Large B-cell Lymphoma

Recruiting·UUniversity of Texas Southwestern Medical Center·Phase 1/2·NCT06768905·30 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Iomab-B. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Iomab-B compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Iomab-B. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Actinium Pharmaceuticals company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Monoclonal antibody[2]
Highest Phase: Phase 3[1]
Company: AActinium Pharmaceuticals

Iomab-B

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Q2 2030

Trials by Indication[1]

Acute Myeloid Leukemia1 trial

Diffuse Large B-Cell Lymphoma1 trial

References

Drug Info

Quick Facts

Related News